Latest news with #ASND
Korea Herald
6 days ago
- Entertainment
- Korea Herald
Red Velvet's Wendy to return as soloist in September
Wendy of Red Velvet is poised to make a comeback as a solo musician in September, according to a local media report on Thursday. Her agency ASND confirmed the news, asking fans to keep their expectations high. Wendy's latest solo endeavor was her second EP 'Wish You Hell,' which came out in March 2024. The six-track set topped the iTunes Top Albums Chart in 21 regions as well as several music charts at home and abroad. The upcoming EP will be her first effort since she left SM Entertainment in April and signed with ASND. Separately, the singer participated in the original soundtrack for the Japanese adaptation of drama 'Marry My Husband,' unveiled earlier in July. She sang 'Blazing Steps' for the Amazon Prime Original based on a hit Korean webtoon of the same title.
Business Insider
15-07-2025
- Business
- Business Insider
Ascendis Pharma announces new data from PaTHway Trial at ENDO 2025
Ascendis Pharma (ASND) announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon PTH continued to provide a durable response in adults with hypoparathyroidism regardless of its cause, including improvements in biochemistries, kidney function, and quality of life. Results were shared at ENDO 2025, the annual meeting of the Endocrine Society being held in San Francisco. PaTHway was a Phase 3, randomized, double-blind, placebo-controlled 26-week trial of 82 adults with chronic hypoparathyroidism, followed by an open-label extension period through Week 182. During the initial 26-week blinded period, participants were randomized 3:1 TransCon PTH:placebo. Renal function was assessed by estimated glomerular filtration rate. Safety assessments included 24-hour urine-calcium and treatment-emergent adverse events. Hypoparathyroidism-related symptoms, functioning, and well-being were measured by the Hypoparathyroidism Patient Experience Scale. Overall retention in the trial was high, with 73 of the original 82 adults enrolled completing the 3.5-year trial. At Week 156, 64 patients had normal albumin-adjusted serum calcium levels and 70 patients were independent from conventional therapy. Reflecting clinically meaningful improvements in kidney function, improvements in eGFR from baseline were sustained through Week 156: mean eGFR increased by 8.76 mL/min/1.73 m2 across all participants and by 13.98 mL/min/1.73 m2 in participants with baseline eGFR less than 60. Patients in the trial reported continued improvements from baseline in their hypoparathyroidism-related symptoms and health-related quality of life and showed continued normalization of 24-hour urine calcium excretion through Week 156. In the trial, TransCon PTH treatment was generally well-tolerated, with no new safety signals identified. TEAEs were mostly mild or moderate and no serious TEAEs or discontinuations were related to study drug. Elevate Your Investing Strategy:
Yahoo
24-06-2025
- Business
- Yahoo
Oppenheimer Hikes Ascendis Pharma Price Target on Strong Yorvipath Demand Outlook
Ascendis Pharma A/S (NASDAQ:ASND) is one of billionaire Stan Druckenmiller's top stock picks with huge upside potential. Oppenheimer maintained its Outperform rating on Ascendis Pharma A/S (NASDAQ:ASND) while increasing its price target from $215 to $224 on June 13. The change comes after a commissioned survey of 20 endocrinologists in the United States who treat hypoparathyroidism showed a high initial demand for the company's drug, Yorvipath. According to doctors, 20–30% of their hypoparathyroid patients are expected to be taking the medication within a year. According to the poll, 90% of physicians would recommend Yorvipath to maintain kidney function before renal impairment develops. This affinity is consistent with the prevalence of renal impairment among patients with hypoparathyroidism. The primary barriers to adoption, according to the majority of physicians, are access and reimbursement; however, Oppenheimer indicated that these worries 'may be more anticipation than reality.' Yorvipath's first full quarter in the United States was described by the firm as 'just the beginning of a launch that will outpace expectations.' Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops and distributes novel treatments for unmet medical needs, especially in the fields of oncology and endocrinology. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
14-06-2025
- Business
- Yahoo
Ascendis Pharma price target raised to $224 from $215 at Oppenheimer
Oppenheimer raised the firm's price target on Ascendis Pharma (ASND) to $224 from $215 and keeps an Outperform rating on the shares. The firm's commissioned survey of 20 U.S. hypoparathyroid-treating endocrinologists indicates robust early demand for Yorvipath, with about 20%-30% of its respondents' hypoPT patients expected to be on drug one year hence. While this lines up with the renal impairment rate across the hypoPT population, 90% of its surveyed physicians would reach for Yorvi to preserve kidney function ahead of such impairment. Access/reimbursement was pointed to as the largest adoption hurdle by most of the docs, but this may be more anticipation than reality. Oppenheimer believes Yorvi's strong first full U.S. quarter was just the beginning of a launch that will outpace expectations. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on ASND: Disclaimer & DisclosureReport an Issue Ascendis Pharma Grants Employee Warrants to Boost Retention Ascendis Pharma's TransCon CNP and hGH Combination Therapy: Best-in-Class Efficacy and Market Potential Justify Buy Rating Ascendis Pharma's Promising Growth Potential Backed by Strong Trial Results and Product Launches Ascendis Pharma Reveals Promising Interim Results from COACH Trial for Achondroplasia Ascendis Pharma Reports Promising Interim Results from COACH Trial
Yahoo
13-06-2025
- Business
- Yahoo
TransCon® hGH Boosts TransCon® CNP Results in Kids with Achondroplasia by Week 26
Ascendis Pharma A/S (NASDAQ:ASND) is among the 13 Biotech Stocks with Huge Upside Potential. It reported interim Week 26 data from its Phase 2 COACH Trial, confirming that combining TransCon hGH (lonapegsomatropin) with TransCon CNP (navepegritide) raised annualized growth velocity (AGV) and height Z-scores in children with achondroplasia. A close-up view of a hand manipulating a syringe while delivering TransCon CNP into a tumor. A mean AGV of 9.14 cm/year and a +0.53 Z-score rise were attained by treatment-naïve youngsters (N=12). Children (N=9) treated with TransCon CNP in the past achieved an AGV of 8.25 cm/year with a +0.44 Z-score improvement. The majority of side effects were modest, and safety remained consistent with monotherapies. The COACH Trial is the first to assess this combination in kids between the ages of two and eleven. While TransCon CNP is undergoing FDA priority review, TransCon hGH is approved as SKYTROFA® for juvenile growth hormone insufficiency. The treatment focuses on the FGFR3-CNP signaling imbalance that is at the heart of achondroplasia, a disorder that affects more than 250,000 people worldwide. It is anticipated that the results of week 52 and a scheduled Phase 3 trial in Q4 2025 will further clarify efficacy and long-term benefits. The biopharmaceutical business Ascendis Pharma A/S (NASDAQ:ASND) uses its TransCon technology platform to significantly improve patient outcomes. While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None.
